Exendin‐4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation
| العنوان: | Exendin‐4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation |
|---|---|
| المؤلفون: | Yi Yu, Yuanyuan Shao, Guoliang Feng, Junhe Li, Wei Huang, He Wenjing |
| المصدر: | The Prostate. 80:367-375 |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, endocrine system, Urology, Mice, Nude, Cell Growth Processes, Glucagon-Like Peptide-1 Receptor, Random Allocation, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Cell Movement, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Phenylthiohydantoin, LNCaP, Animals, Humans, Enzalutamide, Medicine, Neoplasm Invasiveness, Tumor growth, Protein kinase B, PI3K/AKT/mTOR pathway, Cell Nucleus, Mice, Inbred BALB C, business.industry, digestive, oral, and skin physiology, Invasion and migration, Prostatic Neoplasms, Drug Synergism, medicine.disease, Xenograft Model Antitumor Assays, Enzyme Activation, 030104 developmental biology, Oncology, chemistry, Receptors, Androgen, Cell culture, 030220 oncology & carcinogenesis, Benzamides, Cancer research, Exenatide, business, Proto-Oncogene Proteins c-akt |
| الوصف: | BACKGROUND Glucagon-like peptide 1 (GLP-1) and its analogs are first-line choices for the treatment of type 2 diabetes mellitus. Recent studies have shown that they exhibit antitumor properties in some tumors. We previously found that a GLP-1 analog, exendin-4 (Ex-4), inhibited the growth of prostate cancer cells through suppressing the PI3K/Akt/mTOR pathway, which is activated in response to enzalutamide treatment and reported to be closely related to resistance to enzalutamide. So we speculated that exendin-4 may enhance the sensitivity of prostate cancer to enzalutamide through inhibiting Akt activation. METHODS LNCap and CWR22RV1 cell lines, as well as mice bearing xenografts formed from the two cells, were used. RESULTS Exendin-4 in combination with enzalutamide dramatically suppressed tumor growth of prostate cancer cells compared to enzalutamide alone; exendin-4 is capable of antagonizing enzalutamide-induced invasion and migration of both prostate cancer cells (P |
| تدمد: | 1097-0045 0270-4137 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f46e3715816f7a48647f549a0f999c8Test https://doi.org/10.1002/pros.23951Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....7f46e3715816f7a48647f549a0f999c8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10970045 02704137 |
|---|